Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries
The DOI matches its Crossref record, with a small difference in title or year; 39 of the 45 references it cites were found in a registry or an index.
Abstract
Background The large observed variability in hemophilia prevalence prevents robust estimation of burden of disease. Objective To estimate the prevalence and prevalence at birth of hemophilia and the associated life expectancy disadvantage. Design Random-effects meta-analysis of registry data. Setting Australia, Canada, France, Italy, New Zealand, and the United Kingdom. Participants Male patients with hemophilia A or B. Measurements Prevalence of hemophilia as a proportion of cases to the male population, prevalence of hemophilia at birth as a proportion of cases to live male births by year of birth, life expectancy disadvantage as a 1 - ratio of prevalence to prevalence at birth, and expected number of patients worldwide based on prevalence in high-income countries and prevalence at birth. Results Prevalence (per 100 000 males) is 17.1 cases for all severities of hemophilia A, 6.0 cases for severe hemophilia A, 3.8 cases for all severities of hemophilia B, and 1.1 cases for severe hemophilia B. Prevalence at birth (per 100 000 males) is 24.6 cases for all severities of hemophilia A, 9.5 cases for severe hemophilia A, 5.0 cases for all severities of hemophilia B, and 1.5 cases for severe hemophilia B. The life expectancy disadvantage for high-income countries is 30% for hemophilia A, 37% for severe hemophilia A, 24% for hemophilia B, and 27% for severe hemophilia B. The expected number of patients with hemophilia worldwide is 1 125 000, of whom 418 000 should have severe hemo…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HA and hemophilia B (HB) are X-linked monogenic disorders resulting from decreased/absent function of coagulation FVIII or FIX.165,166”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [165]
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Random-effects model for meta-analysis of clinical trials: An update
DerSimonian, R., & Kacker, R. (2007) · Contemporary Clinical Trials · doi:10.1016/j.cct.2006.04.004 · Cited by 2,374
Evidence-based health policy—lessons from the Global Burden of Disease Study
Murray, C. J. L., & Lopez, A. D. (1996) · Science · doi:10.1126/science.274.5288.740 · Cited by 2,178
Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A
Lakich, D., Kazazian, H. H., Antonarakis, S. E., & Gitschier, J. (1993) · Nature Genetics · doi:10.1038/ng1193-236 · Cited by 788
Darby, S. C., Kan, S. W., Spooner, R. J., Giangrande, P. L. F., Hill, F. G. H., Hay, C. R. M., Lee, C. A., Ludlam, C. A., & Williams, M. (2007) · Blood · doi:10.1182/blood-2006-10-050435 · Cited by 511
Gringeri, A., Mantovani, L. G., Scalone, L., Mannucci, P. M., & the COCIS Study Group (2003) · Blood · doi:10.1182/blood-2003-03-0941 · Cited by 372
Occurrence of hemophilia in the United States
Soucie, J. M., Evatt, B., Jackson, D., & the Hemophilia Surveillance System Project Investigators (1998) · American Journal of Hematology · doi:10.1002/(sici)1096-8652(199812)59:4<288::aid-ajh4>3.0.co;2-i · Cited by 346
A study of variations in the reported haemophilia A prevalence around the world
STONEBRAKER, J. S., BOLTON‐MAGGS, P. H. B., MICHAEL SOUCIE, J., WALKER, I., & BROOKER, M. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2009.02127.x · Cited by 296
Self-citation450 million years of hemostasis
Davidson, C. J., Tuddenham, E. G., & McVey, J. H. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00334.x · Cited by 169
Mortality and causes of death in Italian persons with haemophilia, 1990–2007
TAGLIAFERRI, A., RIVOLTA, G. F., IORIO, A., OLIOVECCHIO, E., MANCUSO, M. E., MORFINI, M., ROCINO, A., MAZZUCCONI, M. G., FRANCHINI, M., & ON BEHALF OF THE ITALIAN ASSOCIATION OF HEMOPHILIA CENTERS (2010) · Haemophilia · doi:10.1111/j.1365-2516.2009.02188.x · Cited by 168
Self-citation
Cited by
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
How are systematic reviews of prevalence conducted? A methodological study
on behalf of the Prevalence Estimates Reviews – Systematic Review Methodology Group (PERSyst), Borges Migliavaca, C., Stein, C., Colpani, V., Barker, T. H., Munn, Z., & Falavigna, M. (2020) · BMC Medical Research Methodology · doi:10.1186/s12874-020-00975-3 · Cited by 359
Hemophilia therapy: the future has begun
Mannucci, P. M. (2020) · Haematologica · doi:10.3324/haematol.2019.232132 · Cited by 223
The World Federation of Hemophilia Annual Global Survey 1999‐2018
Stonebraker, J. S., Bolton‐Maggs, P. H. B., Brooker, M., Evatt, B. L., Iorio, A., Makris, M., O’Mahony, B., Skinner, M. W., Coffin, D., Pierce, G. F., et al. (2020) · Haemophilia · doi:10.1111/hae.14012 · Cited by 140
Self-citationKlamroth, R., Hayes, G., Andreeva, T., Gregg, K., Suzuki, T., Mitha, I. H., Hardesty, B., Shima, M., Pollock, T., Slev, P., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2021.287 · Cited by 118
Soucie, J. M., Miller, C. H., Dupervil, B., Le, B. C., & Buckner, T. W. (2020) · Haemophilia · doi:10.1111/hae.13998 · Cited by 114
Chowdary, P., Carcao, M. D., Kenet, G., & Pipe, S. W. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02139-1 · Cited by 113
Hemophilia treatment innovation: 50 years of progress and more to come
Mannucci, P. M. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2022.12.029 · Cited by 110
Rezende, S. M., Neumann, I., Angchaisuksiri, P., Awodu, O. A., Boban, A., Cuker, A. C., Curtin, J. A., Fijnvandraat, K., Gouw, S. C., Gualtierotti, R., et al. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.05.026 · Cited by 96
Self-citationPierce, G. F., Adediran, M., Diop, S., Dunn, A. L., Ekiaby, M. E., Kaczmarek, R., Konkle, B. A., Pipe, S. W., Skinner, M. W., Valentino, L. A., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00209-5 · Cited by 88
Long, B. R., Veron, P., Kuranda, K., Hardet, R., Mitchell, N., Hayes, G. M., Wong, W. Y., Lau, K., Li, M., Hock, M. B., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.008 · Cited by 76
Mortality in congenital hemophilia A – a systematic literature review
Hay, C. R. M., Nissen, F., & Pipe, S. W. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15189 · Cited by 76
Mahlangu, J. N., Lamas, J. L., Morales, J. C., Malan, D. R., Šalek, S. Z., Wang, M., Boggio, L. N., Hegemann, I., Mital, A., Cardinal, M., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18420 · Cited by 64
Coffin, D., Gouider, E., Konkle, B. A., Hermans, C. R. J. R., Lambert, C., Diop, S., Ayoub, E., Tootoonchian, E., Youttananukorn, T., Dakik, P., et al. (2023) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2023.102264 · Cited by 64
Self-citationBiological mechanisms underlying inter‐individual variation in factor VIII clearance in haemophilia
Turecek, P. L., Johnsen, J. M., Pipe, S. W., O’Donnell, J. S., & the iPATH study group (2020) · Haemophilia · doi:10.1111/hae.14078 · Cited by 61
Hemophilia A gene therapy: current and next-generation approaches
Pipe, S. W., Gonen-Yaacovi, G., & Segurado, O. G. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2002842 · Cited by 57
Hemophilia gene therapy—New country initiatives
Reiss, U. M., Zhang, L., & Ohmori, T. (2020) · Haemophilia · doi:10.1111/hae.14080 · Cited by 54
Discussing investigational AAV gene therapy with hemophilia patients: A guide
Sidonio, R. F., Pipe, S. W., Callaghan, M. U., Valentino, L. A., Monahan, P. E., & Croteau, S. E. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100759 · Cited by 54
Bolous, N. S., Chen, Y., Wang, H., Davidoff, A. M., Devidas, M., Jacobs, T. W., Meagher, M. M., Nathwani, A. C., Neufeld, E. J., Piras, B. A., et al. (2021) · Blood · doi:10.1182/blood.2021010864 · Cited by 51
Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972–2019
Hassan, S., van Balen, E. C., Smit, C., Mauser‐Bunschoten, E. P., van Vulpen, L. F. D., Eikenboom, J. C. J., Beckers, E. A. M., Hooimeijer, H. L., Ypma, P. F., Nieuwenhuizen, L., et al. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15424 · Cited by 51
van Balen, E. C., O’Mahony, B., Cnossen, M. H., Dolan, G., Blanchette, V. S., Fischer, K., Gue, D., O’Hara, J., Iorio, A., Jackson, S. C., et al. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12488 · Cited by 50
Self-citationValentino, L. A., Baker, J., Butler, R. B., Escobar, M. A., Frick, N., Karp, S., Koulianos, K., Lattimore, S., Nugent, D. J., Pugliese, J. N., et al. (2021) · Journal of Blood Medicine · doi:10.2147/jbm.s325031 · Cited by 50
Recent Advances in Gene Therapy for Hemophilia: Projecting the Perspectives
Chernyi, N., Gavrilova, D., Saruhanyan, M., Oloruntimehin, E. S., Karabelsky, A. V., Bezsonov, E. E., & Malogolovkin, A. S. (2024) · Biomolecules · doi:10.3390/biom14070854 · Cited by 48
Women and bleeding disorders: diagnostic challenges
James, P. (2020) · Hematology · doi:10.1182/hematology.2020000140 · Cited by 48
Mathews, N., Rivard, G., & Bonnefoy, A. (2021) · Journal of Blood Medicine · doi:10.2147/jbm.s271744 · Cited by 47
Fong, S., Handyside, B., Sihn, C., Liu, S., Zhang, L., Xie, L. Y., Murphy, R., Galicia, N., Yates, B., Minto, W. C., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.07.005 · Cited by 47
Diagnosis and treatment challenges in lower resource countries: State‐of‐the‐art
Mahlangu, J. N., Diop, S., & Lavin, M. (2024) · Haemophilia · doi:10.1111/hae.14956 · Cited by 45
Barco, S., Sollfrank, S., Trinchero, A., Adenaeuer, A., Abolghasemi, H., Conti, L., Häuser, F., Hovinga, J. A. K., Lackner, K. J., Loewecke, F., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14805 · Cited by 45
Non‐severe haemophilia: Is it benign? – Insights from the PROBE study
Chai‐Adisaksopha, C., Noone, D., Curtis, R., Frick, N., Nichol, M. B., Germini, F., O’Mahony, B., Page, D., Stonebraker, J. S., Skinner, M. W., et al. (2020) · Haemophilia · doi:10.1111/hae.14105 · Cited by 41
Self-citationKönigs, C., Ozelo, M. C., Dunn, A. L., Kulkarni, R., Nolan, B., Brown, S. A., Schiavulli, M., Gunawardena, S. W., Mukhopadhyay, S., Jayawardene, D. A., et al. (2022) · Blood · doi:10.1182/blood.2021013563 · Cited by 41
Song, X., Zhong, J., Xue, F., Chen, L., Li, H., Yuan, D., Xie, J., Shi, J., Zhang, L., Wu, E. Q., et al. (2020) · Haemophilia · doi:10.1111/hae.14217 · Cited by 39
The Hemophilia Gene Therapy Patient Journey: Questions and Answers for Shared Decision-Making
Wang, M., Négrier, C., Drießler, F., Goodman, C. S., & Skinner, M. W. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s355627 · Cited by 39
Translating the success of prophylaxis in haemophilia to von Willebrand disease
Miesbach, W., & Berntorp, E. E. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2020.12.030 · Cited by 37
Jang, H., von Drygalski, A., Wong, J., Zhou, J. Y., Aguero, P., Lü, X., Cheng, X., Ball, S. T., Ma, Y., Chang, E. Y., et al. (2020) · Magnetic Resonance in Medicine · doi:10.1002/mrm.28388 · Cited by 35
Health care resource utilization and cost burden of hemophilia B in the United States
Buckner, T. W., Bocharova, I., Hagan, K. A., Bensimon, A. G., Yang, H., Wu, E. Q., Sawyer, E. K., & Li, N. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003424 · Cited by 35
Sihn, C., Handyside, B., Liu, S., Zhang, L., Murphy, R., Yates, B., Xie, L. Y., Torres, R., Russell, C. B., O’neill, C. A., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.12.004 · Cited by 35
Burke, T., Asghar, S., O’Hara, J., Chuang, M., Sawyer, E. K., & Li, N. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-02152-1 · Cited by 35
Emerging Therapies in Hemophilia: Improving Equitable Access to Care
Lewandowska, M., Nasr, S., & Shapiro, A. D. (2025) · Journal of Blood Medicine · doi:10.2147/jbm.s490588 · Cited by 34
Haemophilia, state of the art and new therapeutic opportunities, a regulatory perspective
Tomeo, F., Mariz, S., Brunetta, A. L., Stoyanova-Beninska, V. V., Penttilä, K., & Magrelli, A. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14838 · Cited by 34
The Clinical Genetics of Hemophilia B (Factor IX Deficiency)
Miller, C. H. (2021) · The Application of Clinical Genetics · doi:10.2147/tacg.s288256 · Cited by 34
B cell–activating factor modulates the factor VIII immune response in hemophilia A
Doshi, B. S., Rana, J., Castaman, G., Shaheen, M. A., Kaczmarek, R., Butterfield, J. S. S., Meeks, S. L., Leissinger, C., Biswas, M., & Arruda, V. R. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142906 · Cited by 33
Kenet, G., Chen, Y., Lowe, G., Percy, C. L., Tran, H. A., von Drygalski, A., Trossaërt, M., Reding, M. T., Oldenburg, J., Mingot‐Castellano, M. E., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245959 · Cited by 33
Prophylaxis for hemophilia A without inhibitors: treatment options and considerations
Valentino, L. A., & Khair, K. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1775576 · Cited by 33
Nolan, B., Klukowska, A., Shapiro, A. D., Rauch, A., Recht, M., Ragni, M. V., Curtin, J. A., Gunawardena, S. W., Mukhopadhyay, S., Jayawardene, D. A., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020004085 · Cited by 32
Expanding global access to genetic therapies
Muigai, A. W. T. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-01191-0 · Cited by 32
Therapeutic and technological advancements in haemophilia care: Quantum leaps forward
Lewandowska, M., Nasr, S., & Shapiro, A. D. (2022) · Haemophilia · doi:10.1111/hae.14531 · Cited by 32
Fitusiran: The first approved siRNA therapy for hemophilia via reducing plasma antithrombin levels
Lu, D., Dou, F., & Gao, J. (2025) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2025.01031 · Cited by 31
Ay, C., Kovacevic, K. D., Kraemmer, D., Schoergenhofer, C., Gelbenegger, G., Firbas, C., Quehenberger, P., Jilma‐Stohlawetz, P., Gilbert, J. C., Zhu, S., et al. (2022) · Blood · doi:10.1182/blood.2022016571 · Cited by 31
Self-citationHemophilia a patients with inhibitors: Mechanistic insights and novel therapeutic implications
Luo, L., Zheng, Q., Chen, Z., Huang, M., Fu, L., Hu, J., Shi, Q., & Chen, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1019275 · Cited by 31
Preclinical development of plant‐based oral immune modulatory therapy for haemophilia B
Srinivasan, A., Herzog, R. W., Khan, I. H., Sherman, A., Bertolini, T. B., Wynn, T., & Daniell, H. (2021) · Plant Biotechnology Journal · doi:10.1111/pbi.13608 · Cited by 31
Hemophilia gene therapy: first, do no harm
Valentino, L. A., Kaczmarek, R., Pierce, G. F., Noone, D., O’Mahony, B., Page, D., Rotellini, D., & Skinner, M. W. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.06.016 · Cited by 30
Hemophilia B (Factor IX Deficiency)
Sidonio, R. F., & Malec, L. M. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.07.008 · Cited by 29
Hmida, J., Hilberg, T., Ransmann, P., Tomschi, F., Klein, C., Koob, S., Franz, A., Richter, H., Oldenburg, J., & Strauss, A. C. (2022) · Haemophilia · doi:10.1111/hae.14564 · Cited by 29
The ethics of gene therapy for hemophilia: a narrative review
Baas, L., van der Graaf, R., van Hoorn, E. S., Bredenoord, A. L., & Meijer, K. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2022.12.027 · Cited by 29
Favaloro, E. J., & Pasalic, L. (2023) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2023.102143 · Cited by 28
Hermans, C. R. J. R., Johnsen, J. M., & Curry, N. S. (2024) · Haemophilia · doi:10.1111/hae.14983 · Cited by 28
Hemophilic Arthropathy: Barriers to Early Diagnosis and Management
Cuesta‐Barriuso, R., Donoso‐Úbeda, E., Meroño‐Gallut, J., Ucero‐Lozano, R., & Pérez‐Llanes, R. (2022) · Journal of Blood Medicine · doi:10.2147/jbm.s343924 · Cited by 27
Deshpande, S., Joseph, K., Tong, J., Chen, Y., Pishko, A. M., & Cuker, A. C. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014111 · Cited by 27
Exercise capacity in people with haemophilia: A systematic review
Cruz‐Montecinos, C., Núñez‐Cortés, R., Vasconcello‐Castillo, L., Solís‐Navarro, L., Carrasco‐Alonso, B., Calatayud, J., Pérez‐Alenda, S., & Torres‐Castro, R. (2022) · Haemophilia · doi:10.1111/hae.14646 · Cited by 26
Hemophilia care in Africa: Status and challenges
Mbanya, D., Diop, S., Ndoumba, A. M., & Kiaby, M. E. (2021) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2021.01.008 · Cited by 26
Chimeno‐Hernández, A., Querol‐Giner, F., Pérez‐Alenda, S., Núñez‐Cortés, R., Cruz‐Montecinos, C., Carrasco, J. J., & Aguilar‐Rodríguez, M. (2022) · Haemophilia · doi:10.1111/hae.14556 · Cited by 25
Santana, I. R., DasMahapatra, P., Burke, T., Hakimi, Z., Bartelt-Hofer, J., Nazir, J., & O’Hara, J. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02300-1 · Cited by 25
Wang, R., Wang, Z., Gu, Y., Zhang, J., Wang, P., Tong, P., & Lv, S. (2022) · Journal of Orthopaedics and Traumatology · doi:10.1186/s10195-022-00648-5 · Cited by 25
Von Willebrand Disease: Gaining a global perspective
O’Sullivan, J. M., Tootoonchian, E., Ziemele, B., Makris, M., Federici, A. B., Khayat, C. D., Ekiaby, M. E., Rotellini, D., Sidonio, R. F., Iorio, A., et al. (2023) · Haemophilia · doi:10.1111/hae.14804 · Cited by 25
Self-citationCellular stress and coagulation factor production: when more is not necessarily better
Chen, Z., Herzog, R. W., & Kaufman, R. J. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.10.005 · Cited by 25
In vivo LNP-CRISPR Approaches for the Treatment of Hemophilia
Lee, J. H., & Han, J. P. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00705-1 · Cited by 25
Reported prevalence of von Willebrand disease worldwide in relation to income classification
Stonebraker, J. S., Iorio, A., Lavin, M., Rezende, S. M., Srivastava, A., Pierce, G. F., Coffin, D., Tootoonchian, E., & Makris, M. (2023) · Haemophilia · doi:10.1111/hae.14810 · Cited by 24
Self-citationArthropathy in people with mild haemophilia: Exploring risk factors
la Corte‐Rodríguez, H. D., Rodriguez-Merchan, E. C., Román, M. T. Á., Martín‐Salces, M., Rivas‐Pollmar, I., & Jiménez‐Yuste, V. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.01.010 · Cited by 24
Nugent, D. J., Acharya, S. S., Baumann, K., Bedrosian, C. L., Bialas, R., Brown, K. M., Corzo, D., Haidar, A., Hayward, C. P. M., Marks, P. W., et al. (2023) · Expert Review of Hematology · doi:10.1080/17474086.2023.2175661 · Cited by 23
Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B
Olasupo, O. O., Noronha, N., Lowe, M. S., Ansel, D., Bhatt, M. D., & Matino, D. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014544.pub2 · Cited by 23
Benefits and limitations of extended plasma half-life factor VIII products in hemophilia A
Mannucci, P. M. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1723547 · Cited by 23
Hemophilia management: Huge impact of a tiny difference
Kloosterman, F. R., Zwagemaker, A., Abdi, A., Gouw, S. C., Castaman, G., & Fijnvandraat, K. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12314 · Cited by 23
Real‐world analysis of haemophilia patients in China: A single centre's experience
Song, X., Liu, W., Xue, F., Zhong, J., Yang, Y., Liu, Y., Xie, J., Wu, E. Q., Zhang, L., Shi, J., et al. (2020) · Haemophilia · doi:10.1111/hae.14029 · Cited by 23
O’Hara, J., Noone, D., Jain, M. M., Pedra, G., Landis, S., Hawes, C. R., Burke, T., & Camp, C. (2021) · Haemophilia · doi:10.1111/hae.14302 · Cited by 22
CRISPR/Cas9-Mediated in vivo Genetic Correction in a Mouse Model of Hemophilia A
Luo, S., Li, Z., Dai, X., Zhang, R., Liang, Z., Li, W., Zeng, M., Su, J., Wang, J., Liang, X., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.672564 · Cited by 22
Cotino, C., Pérez‐Alenda, S., Cruz‐Montecinos, C., López‐Bueno, R., Núñez‐Cortés, R., Suso‐Martí, L., Méndez-Rebolledo, G., Andersen, L. L., Casaña, J., & Calatayud, J. (2023) · Haemophilia · doi:10.1111/hae.14828 · Cited by 22
Vagus nerve stimulation primes platelets and reduces bleeding in hemophilia A male mice
Bravo‐Iñiguez, C. E., Fritz, J. R., Shukla, S., Sarangi, S. N., Thompson, D., Amin, S. G., Tsaava, T., Chaudhry, S., Valentino, S. P., Hoffman, H. B., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38505-6 · Cited by 21
Gentherapie der Hämophilie: Empfehlung der Gesellschaft für Thrombose- und Hämostaseforschung (GTH)
Miesbach, W., Oldenburg, J., Klamroth, R., Eichler, H., Koscielny, J., Holzhauer, S., Holstein, K., Hovinga, J. A. K., Alberio, L., Olivieri, M., et al. (2022) · Hämostaseologie · doi:10.1055/a-1957-4477 · Cited by 21
Foundations of hemophilia and epidemiology
Paris, L. Q. (2023) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000001222 · Cited by 20
Regulation and importance of factor VIII levels in hemophilia A carriers
Cygan, P. H., & Kouides, P. A. (2021) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000667 · Cited by 20
Mahdavi, A., Mohammadi, H., Bagherniya, M., Foshati, S., Clark, C. C. T., Moafi, A., Elyasi, M., & Rouhani, M. H. (2021) · British Journal Of Nutrition · doi:10.1017/s0007114521004839 · Cited by 20
Oka, G., Roussel‐Robert, V., Levivien, C., Lopez, I., & Pieragostini, R. (2023) · Haemophilia · doi:10.1111/hae.14755 · Cited by 20
Nurse‐led education of people with bleeding disorders and their caregivers: A scoping review
Ballmann, J., & Ewers, M. (2022) · Haemophilia · doi:10.1111/hae.14629 · Cited by 19
Cost of hemophilia A in Turkey: an economic disease burden analysis
Malhan, S., Öksüz, E., Antmen, B., Ar, M. C., Balkan, C., & Kavaklı, K. (2021) · Journal of Medical Economics · doi:10.1080/13696998.2021.1965388 · Cited by 19
Descriptive analysis of bleeding symptoms in haemophilia carriers enrolled in the ATHNdataset
Puetz, J., & Cheng, D. (2021) · Haemophilia · doi:10.1111/hae.14422 · Cited by 19
Iorio, A., Königs, C., Reding, M. T., Rotellini, D., Skinner, M. W., Mancuso, M. E., & Berntorp, E. E. (2022) · Haemophilia · doi:10.1111/hae.14676 · Cited by 19
Self-citationCurrent factor IX replacement options for hemophilia B and the challenges ahead
Franchini, M., Zaffanello, M., & Focosi, D. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2196012 · Cited by 19
Kingsmore, S. F., Wright, M. S., Smith, L. D., Liang, Y., Mowrey, W. R., Protopsaltis, L., Bainbridge, M., Baker, M. W., Batalov, S., Blincow, E., et al. (2024) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2024.10.021 · Cited by 18
The role of public health in rare diseases: hemophilia as an example
El-Sayed, A., Reiss, U. M., Hanna, D. A., & Bolous, N. S. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1450625 · Cited by 18
Tratamiento moderno de la hemofilia y el desarrollo de terapias innovadoras
Ruiz‐Sàez, A. (2021) · Investigación Clínica · doi:10.22209/ic.v62n1a07 · Cited by 17
Ay, C., Frenzel, L., Pinachyan, K., & Quellec, S. L. (2023) · Haemophilia · doi:10.1111/hae.14907 · Cited by 17
Outcome measures in hemophilia: current and future perspectives
Benemei, S., Boni, L., & Castaman, G. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2365929 · Cited by 17
Contemporary approaches to treat people with hemophilia: what’s new and what’s not?
Valentino, L. A., Santaella, M. E. E., Carlson, S. A., & Recht, M. (2025) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2025.102696 · Cited by 17
Santana, I. R., DasMahapatra, P., Burke, T., Hakimi, Z., Bartelt-Hofer, J., Nazir, J., & O’Hara, J. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02301-0 · Cited by 17
Wells, A. J., & Stephensen, D. (2020) · British Journal of Hospital Medicine · doi:10.12968/hmed.2020.0016 · Cited by 17
O'Donovan, M. T., Bergin, C., Quinn, E., Singleton, E., Roche, S., Benson, J., Bird, R., Byrne, M., Duggan, C., Gilmore, R., et al. (2021) · Haemophilia · doi:10.1111/hae.14307 · Cited by 17
Haemophilia in France: Modelisation of the Clinical Pathway for Patients
Beny, K., de Vigneulles, B. D. S., Carrouel, F., Bourgeois, D. M., Gay, V., Négrier, C., & Dussart, C. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19020646 · Cited by 17
Efanesoctocog alfa for the prevention and treatment of bleeding in patients with hemophilia A
Konkle, B. A. (2023) · Expert Review of Hematology · doi:10.1080/17474086.2023.2223925 · Cited by 16
Miesbach, W., Konkle, B. A., Chowdary, P., Kaczmarek, R., Leebeek, F. W. G., Mahlangu, J. N., Makris, M., Pipe, S. W., Srivastava, A., Voorberg, J., et al. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.12.039 · Cited by 16
Self-citationMancuso, M. E., Biss, T. T., Fischer, K., Enriquez, M. M., Steele, M., Wang, M., Tseneklidou‐Stoeter, D., Ahuja, S. P., & Kenet, G. (2021) · Haemophilia · doi:10.1111/hae.14294 · Cited by 16
Metadata
- Authors
- Iorio, A., Stonebraker, J. S., Chambost, H., Makris, M., Coffin, D., Herr, C., Germini, F., & for the Data and Demographics Committee of the World Federation of Hemophilia*
- Affiliations
- McMaster University (CA)
- North Carolina State University (US)
- La Timone Hospital of Assistance Publique – Hôpitaux de Marseille, Aix-Marseille University, Institut National de la Santé et de la Recherche Médicale, and Institut National de la Recherche Agronomique, Marseille, France (H.C.)
- University of Sheffield (GB)
- World Federation of Hemophilia (CA)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2019-10-15
- Volume
- 171
- Issue
- 8
- Pages
- 540-546
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2972722566
- Cited by
- 462
- References
- 45
- Citations by year
- 2026: 57 · 2025: 76 · 2024: 80 · 2023: 71 · 2022: 75 · 2021: 64 · 2020: 34 · 2019: 4
- FWCI
- 7.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
- Annals of Internal Medicine
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Keywords
- hemophilia, hemophilia A, hemophilia B, prevalence, life expectancy, disease burden, severe hemophilia, years of life lost
- MeSH terms
- Australia, Canada, France, United Kingdom, Hemophilia A, Humans, Infant, Newborn, Italy, Life Expectancy, Male, New Zealand, Registries, Prevalence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.